로딩 중…
StockDiggingStockDigging

AbbVie Inc.

ABBV· NYSE
$216.60-2.09%
2026-06-18

Price Chart

AbbVie Inc.+19.58%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$382.69B
Revenue$62.82B
Net Income$3.64B
Total Assets$136.46B
Net Assets$27.50B
Employees57,000
Value
P/E105.16x
P/B13.92x
P/S6.09x
EV/EBITDA26.37x
FCF Yield5.45%
Profitability
ROE13.23%
ROA2.67%
Op. Margin27.60%
Revenue Growth12.43%
Earnings Growth-45.65%
Financial Health
Debt Ratio396.25%
Total Debt$72.86B
FCF$20.86B
Cash$9.39B
Current Ratio0.80x
Net Debt/EBITDA3.75x
Dividend
Div. Yield3.09%
Div. Growth4.45%
Performance
1Y Return19.58%
1M Return1.33%
From 52W High-10.17%
1Y MDD-18.00%
Trading
Volume5,041,494 shares
Trading Value$1.10B
Per Share
EPS$2.37

Company Info

CEO Mr. Robert A. Michael CPA
Employees 57,000
HQ North Chicago, United States

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.